Platinum Industries Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2026.

Regulatory Compliance Filing

The company filed the mandatory certificate under Regulation 74(5) of SEBI regulations with both the National Stock Exchange of India Limited (NSE) and BSE Limited on 8th April, 2026. The filing was executed by Bhagyashree Mallawat, Company Secretary and Compliance Officer, ensuring adherence to prescribed timelines.

Certificate Confirmation

Bigshare Services Private Limited, serving as the company's Registrar & Share Transfer Agent (RTA), issued the certificate dated 4th April, 2026. The certificate, signed by Authorised Signatory Akash Shamal, provides confirmation regarding dematerialisation activities during the specified quarter.

The RTA confirmed that no dematerialisation requests for equity shares of Platinum Industries Limited were received during the period from 1st January 2026 to 31st March 2026. This certification aligns with SEBI's circular references NSDL/CIR/II/5/2019 and DSL/OPS/RTA/POLICY/2019/14, both dated 25th January 2019.

Stock Exchange Details

The filing was submitted to both major Indian stock exchanges where the company's shares are listed:

Corporate Governance

This quarterly filing demonstrates Platinum Industries Limited's commitment to maintaining regulatory compliance and transparent corporate governance practices. The timely submission of the certificate ensures the company meets all statutory requirements under SEBI's depositories and participants regulations.

The certificate submission represents part of the company's ongoing compliance framework, with the RTA providing necessary documentation to support regulatory adherence for the fourth quarter of fiscal year 2026.

The pharmaceutical industry is facing a significant challenge as the manufacturing of essential cancer medicines has become economically unviable due to a sharp surge in platinum prices. This development is particularly impacting the production of critical oncology drugs that rely on platinum as a key component.

Impact on Key Cancer Medications

The price surge is specifically affecting the manufacturing of three important cancer treatment compounds:

• Carboplatin: A platinum-based chemotherapy drug used to treat various cancers
• Oxaliplatin: An essential medication for colorectal and other cancer treatments
• Cisplatin: A widely used chemotherapy agent for multiple cancer types

These medications represent cornerstone treatments in oncology, making their production challenges a matter of significant concern for the healthcare sector.

Pharmaceutical Companies Affected

Several major pharmaceutical companies are experiencing the impact of this platinum price surge:

Manufacturing Viability Concerns

The surge in platinum prices has created a direct impact on the cost structure of manufacturing these cancer medicines. Platinum serves as a critical component in the formulation of these compounds, and its price increase has made the production process economically challenging for pharmaceutical manufacturers.

This situation highlights the vulnerability of pharmaceutical supply chains to commodity price fluctuations, particularly for medications that depend on precious metals as active ingredients. The affected companies are now facing difficult decisions regarding the continuation of production for these essential cancer treatments.

Industry Implications

The manufacturing challenges created by rising platinum costs could potentially affect the availability and pricing of these critical cancer medications in the market. Pharmaceutical companies may need to explore alternative sourcing strategies or adjust their production approaches to maintain the supply of these life-saving treatments while managing the increased input costs.